At SXSW in Austin this weekend, consumer genomics company 23andMe unveiled its latest test, a predisposition report on Type 2 diabetes.
The test, which has not undergone FDA clearance and does not purport to diagnose a condition, is designed to help people understand when they’re at a higher-than-normal risk for Type 2 diabetes so they can alter their lifestyle. To assist with the latter piece,...
Apple versus posionous gas. Patently Apple has spotted a newly published patent application that seems to suggest that miniature sensors for poisonous gas may be a feature of future Apple devices.
Filled in March of 2018, the application’s diagrams include examples of the sensors housed within an enclosure such as an Apple Watch and describe detection capabilities for “at least one of ozone (O....
Dr. Bimal Shah and Courtnee Westendorf have been announced as the chief medical officer and chief marketing officer, respectively, of Livongo Health. Shah was promoted internally from a position of SVP of clinical strategy, while Westendorf previously served as the chief marketing officer of the Oakland Raiders football team.
“We are excited to have a leading marketing executive like Courtnee...
This morning, consumer genomic giant 23andMe revealed that it is teaming up with Lark Health, an AI platform that helps users manage chronic conditions, on a new initiative that will integrate a user’s 23andMe genetic information into Lark’s Wellness Program and Diabetes Prevention Program. The idea is that Lark’s AI weight loss and wellness coach will be able to access a user’s genetic...
Yesterday afternoon the FDA announced that it would permit 23andMe to market its Personal Genome Service Pharmacogenetic Reports test. The test offers consumers information on whether they posses one of 33 variants across multiple genes that could impact their body’s ability to metabolize certain medications.
The purpose of this test is to inform patients and encourage them to more thoroughly...
The Cadillac of gene tests? 23andMe is considering a $749 premium gene test offering, considerably more expensive than the $99 to $199 products the company has offered thus far, CNBC reports. Some users received email notifications about a premium service at that price, but clicking the link did nothing. According to 23andMe, it’s only testing user interest and has no plans for a roll out.
In...
23andMe has emailed developers a warning that an API permitting use of anonymized customer datasets for third-party app development will be shut down in approximately two weeks, CNBC reports.
While the raw data will remain available to clinical research partners such as GlaxoSmithKline, which invested $300 million this year to gain access to the genetic testing startup’s DNA database for drug...
A group of consumer genetic and personal genomic testing companies have released a set of best practices for handling consumers’ personal genetic data.
Designed to ensure privacy and promote transparency, the guidelines include a requirement for separate express consent before a company can transfer genetic data to a third party, such as an insurer or employer.
“Supporting strong and transparent...
23andMe on Wednesday announced that GlaxoSmithKline has invested $300 million to gain exclusive access to the genetic testing startup’s DNA database.
The deal comes as GlaxoSmithKline amid reports that GSK is weighing the possibility of a company breakup and investors contending that synergies between consumer markets and big pharma are inherently limited and that GSK’s pharmaceuticals business...
In the last few years consumer genomics has grown in both its offerings and legitimacy. The industry that was once best known for telling clients if they were Italian or Hungarian is now securing its foothold within the healthcare space.
Whether it is uniting women switched at birth 72-years prior or settling neighborly feuds, consumer genomics have caught the public’s interest. The highest...
.jpeg?itok=HF3iI7dj "Person answering their front door and getting a delivery from another person")
